PMID- 7718095
OWN - NLM
STAT- MEDLINE
DCOM- 19950524
LR  - 20220317
IS  - 1046-7408 (Print)
IS  - 1046-7408 (Linking)
VI  - 32
IP  - 4
DP  - 1994 Dec
TI  - Immunotherapy with intravenous immunoglobulin for treatment of recurrent 
      pregnancy loss: American experience.
PG  - 286-9
AB  - PROBLEM: Recurrent spontaneous abortion (RSA) is the cause of childlessness in 
      2-5% of reproducing couples. Immunological mechanisms have been proposed as an 
      etiology in some cases of RSA. Various forms of immunotherapy have been attempted 
      in individuals thought to have an immunologic mechanism associated with RSA. 
      Intravenous immunoglobulin (IVIG) has been used in a pilot study to successfully 
      treat women with RSA. METHOD: To evaluate the efficacy of IVIG in the prevention 
      of RSA as prospective randomized, placebo-controlled clinical trial was 
      undertaken. Women experiencing two or more consecutive RSAs receive either IVIG 
      500 mg/kg/month or placebo (albumin). RESULTS: To date 92 women have been 
      enrolled in the study and 58 pregnancies have been achieved. The outcome of the 
      58 pregnancies include 20 deliveries, 9 ongoing pregnancies and 29 losses. 
      Fourteen (49%) of the 29 pregnancy losses were blighted ova (empty gestational 
      sacs) and 15 (51%) were intrauterine fetal deaths (IUFD's) occurring in the first 
      trimester of pregnancy. Of 14 blighted ova, 8 were in women receiving IVIG and 6 
      were receiving placebo. Fifteen IUFD's occurred: 3 (20%) in women receiving IVIG 
      and 12 (80%) placebo. Of 11 pregnancy losses occurring in women receiving IVIG, 8 
      (73%) were blighted ova and 3 (27%) were IUFD's. Eighteen losses occurred in 
      women receiving placebo: 6 (33%) were blighted ova and 12 (67%) were IUFD's. 
      CONCLUSIONS: These preliminary data suggest IVIG may be effective treatment for 
      RSA. Analysis of data from the completed randomized placebo-controlled trial will 
      test this suggestion.
FAU - Coulam, C B
AU  - Coulam CB
AD  - Reproductive Immunology, Genetics and IVF Institute, Fairfax, VA 22031.
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - Denmark
TA  - Am J Reprod Immunol
JT  - American journal of reproductive immunology (New York, N.Y. : 1989)
JID - 8912860
RN  - 0 (Albumins)
RN  - 0 (Immunoglobulins, Intravenous)
SB  - IM
MH  - Abortion, Habitual/immunology/*therapy
MH  - Adult
MH  - Albumins/administration & dosage
MH  - Double-Blind Method
MH  - Female
MH  - Fetal Death
MH  - Fetal Resorption
MH  - Humans
MH  - Immunoglobulins, Intravenous/*therapeutic use
MH  - *Immunotherapy
MH  - Infant, Newborn
MH  - Pregnancy
MH  - Pregnancy Outcome
MH  - Prospective Studies
MH  - Treatment Outcome
MH  - Virginia
EDAT- 1994/12/01 00:00
MHDA- 1994/12/01 00:01
CRDT- 1994/12/01 00:00
PHST- 1994/12/01 00:00 [pubmed]
PHST- 1994/12/01 00:01 [medline]
PHST- 1994/12/01 00:00 [entrez]
AID - 10.1111/j.1600-0897.1994.tb01127.x [doi]
PST - ppublish
SO  - Am J Reprod Immunol. 1994 Dec;32(4):286-9. doi: 
      10.1111/j.1600-0897.1994.tb01127.x.